Ocular FIP treatment moves from theory to practical care

CURRENT FULL VERSION: Ocular FIP is emerging as one of the clearest examples of how fast feline medicine has changed since antiviral therapy entered mainstream discussion. VetGirl’s podcast “Ocular FIP – A New Vision for Treatment” highlights the latest evidence on antiviral management for feline infectious peritonitis with eye involvement, a presentation that used to carry an especially grim prognosis. The podcast also serves as a reminder that ocular FIP is not a niche footnote: ocular and neurologic involvement are much more common in non-effusive disease than effusive disease, and in some cats the eye findings are the first or dominant clue. Reported lesions span both the anterior and posterior segment, including uveitis, keratic precipitates, iris color change, dyscoria or anisocoria, hyphema, hypopyon, fibrinous exudate, tapetal or non-tapetal retinal lesions, retinal hemorrhage, vascular tortuosity, retinal detachment, and perivascular cuffing. The broader shift is that clinicians now have more published outcome data, more practical dosing experience, and legal access pathways to compounded GS-441524 in the U.S., even though the drug still is not FDA-approved. (fda.gov)

That context matters. FIP was long regarded as almost uniformly fatal, and many U.S. veterinarians and pet parents were pushed toward unregulated supply channels when antiviral treatment began showing promise. In May 2024, the FDA said it does not intend to enforce new animal drug approval requirements for compounded GS-441524 prescribed by a veterinarian for a specific cat with FIP under conditions described in Guidance for Industry #256. The agency also stressed that compounded products from bulk drug substances remain unapproved, and are not technically “legal,” an important distinction for practices navigating client expectations and compliance language. (fda.gov)

Clinical evidence has been moving in parallel. A 2024 systematic review covering studies from 2018 to 2024 concluded that GS-441524 is a highly promising treatment for FIP, with dosing commonly landing in the 5–10 mg/kg once-daily range, then adjusted for disease form, severity, and ocular or neurologic involvement. The review also noted that randomized controlled trials are still needed to establish more standardized protocols. In other words, the field has moved beyond anecdote, but not yet to a fully settled consensus. VetGirl’s related coverage on dosing and duration reflects where that conversation is heading next: not whether antivirals work, but how aggressively to induce remission, how long to continue therapy, and what objective markers should help determine when treatment can safely stop. (pmc.ncbi.nlm.nih.gov)

For ocular disease specifically, one of the more useful clinical signals comes from a JVIM case series of 32 cats treated with injectable remdesivir and oral GS-441524. The authors reported that once cats survived the first three days of therapy, outcomes were strong overall, with 26 of 28 cats alive and in clinical remission at 12 weeks. They also noted that ocular and neurologic cases were started at 15–20 mg/kg daily because of poor access across the blood-ocular and blood-brain barriers. In that series, 4 of 6 cats with ocular involvement recovered fully. A separate case report described successful treatment of a cat with ocular FIP using an oral antiviral containing GS-441524, adding to the evidence that ocular lesions can respond when therapy is sustained and appropriately targeted. VetGirl’s discussion usefully frames the practical takeaway: these cats may improve quickly, but the eye remains one of the sites where undertreatment is most likely to matter. (academic.oup.com)

Access has also become more practical, which is likely part of why educational coverage is broadening now. Cornell’s Feline Health Center reported that Stokes Pharmacy, working with Bova, announced on May 30, 2024 that compounded oral GS-441524 would become available in the U.S. on June 1, 2024. Since then, additional pharmacy players have entered the space; Wedgewood announced in June 2025 that it had added a compounded oral GS-441524 formulation to its FIP treatment offerings. That doesn’t resolve the regulatory gray zone, but it does mean veterinarians and pet parents increasingly have access to pharmacy-dispensed product rather than relying on informal channels. (vet.cornell.edu)

Expert and industry guidance is converging around a few practical themes. The 2025 Feline Veterinary Medical Association FIP update guide supports hospitalization and initial intravenous remdesivir for severely ill cats that cannot reliably take oral medication, followed by transition to oral GS-441524. The same guide is notably more cautious about molnupiravir, reserving it mainly for rescue situations, relapse, treatment failure, or settings where it is the only legal option, citing a narrower therapeutic window and mutagenic or teratogenic concerns. That aligns with the broader clinical impression that GS-441524 remains the preferred backbone therapy when available, while difficult ocular and neurologic cases may need more individualized escalation. VetGirl’s dosing-focused review adds another emerging theme: higher-dose induction may reduce viral burden faster, but early clinical improvement alone is not a reliable signal that virus has cleared from harder-to-penetrate tissues such as the eye and CNS. Investigators are increasingly looking at acute phase proteins such as serum amyloid A and alpha-1 acid glycoprotein, along with the albumin:globulin ratio, as more objective ways to guide duration and treatment termination. (catvets.com)

VetGirl’s broader FIP diagnostic update also helps explain why ocular cases can still be missed or delayed. Most cats are exposed to feline enteric coronavirus, especially in multicat settings, but only a minority go on to develop FIP after viral mutation and macrophage-associated spread. The “classic” patient is young, often under 2 years old, but adults can present as well. Reported real-world antiviral response rates are now often cited around 85% to 90%, yet diagnosis in practice remains presumptive in many cases and still depends on combining signalment, clinicopathologic changes, effusion characteristics when present, imaging, and lesion distribution rather than expecting one definitive test to settle the case. That is especially relevant when ocular inflammation is the presenting complaint.

Why it matters: For veterinary teams, the practical challenge is no longer whether ocular FIP can ever respond, but how to diagnose it early, dose it appropriately, and counsel pet parents realistically. Ocular signs may be part of non-effusive disease, may overlap with neurologic involvement, and may require higher antiviral exposure than more straightforward cases. That raises the stakes for careful ophthalmic examination, baseline lab work, imaging where indicated, and close rechecks to assess response, appetite, weight, inflammation, and any emerging CNS signs. It also means practices need a clear script on the distinction between FDA approval and FDA enforcement discretion, because pet parents are likely to hear simplified or inaccurate claims online. (academic.oup.com)

What to watch: The next phase will likely be better standardization, not a dramatic new discovery: more published outcome data in ocular and neurologic subsets, more guidance on when to raise dose or extend duration, and possibly broader adoption of therapeutic drug monitoring in referral settings. Just as important, clinicians are likely to see more discussion around objective stopping criteria, including trends in serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio, as the field tries to balance shorter, more affordable treatment courses against the risk of stopping too soon in ocular and neurologic disease. Until then, ocular FIP looks increasingly treatable, but still not routine. (pmc.ncbi.nlm.nih.gov)